Aktis Oncology vs Elevance Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

Elevance Health leads in AI visibility (92 vs 67)
Aktis Oncology logo

Aktis Oncology

ChallengerHealthcare & Life Sciences

Radiopharmaceuticals

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

AI VisibilityBeta
Overall Score
B67
Category Rank
#1 of 1
AI Consensus
84%
Trend
up
Per Platform
ChatGPT
72
Perplexity
69
Gemini
68

About

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

Full profile
Elevance Health logo

Elevance Health

LeaderHealthcare Tech

Enterprise

Indianapolis BCBS managed care (NYSE: ELV) ~$175B FY2024 revenue; Anthem renamed 2022, BCBS exclusive in 14 states, Carelon health services, Medicaid/MA medical cost pressure competing with UnitedHealth and Cigna.

AI VisibilityBeta
Overall Score
A92
Category Rank
#194 of 290
AI Consensus
68%
Trend
down
Per Platform
ChatGPT
88
Perplexity
88
Gemini
88

About

Elevance Health, Inc. (formerly Anthem, Inc.) is an Indianapolis, Indiana-based managed care and health services company — publicly traded on the New York Stock Exchange (NYSE: ELV) as an S&P 500 Health Care component — providing health insurance plans under the Blue Cross Blue Shield brand in 14 states (Indiana, Georgia, California, Colorado, Connecticut, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin), Medicare Advantage, Medicaid managed care, and commercial employer-sponsored health plans through Carelon (pharmacy and behavioral health services — formerly IngenioRx) to approximately 47 million medical members through approximately 100,000 employees. In fiscal year 2024, Elevance Health reported revenues of approximately $175 billion (predominantly premium revenues from employer-sponsored and government-program health plan members), with operating income under pressure from medical cost increases in the Medicaid segment (post-COVID health utilization normalization causing medical costs to exceed Medicaid actuarial pricing expectations set during the pandemic period of reduced care utilization). CEO Gail Boudreaux has executed the company's transformation from Anthem to Elevance Health (rebranded June 2022) — reflecting the broadened value proposition beyond health insurance into health services: Carelon Services (behavioral health, pharmacy benefit management, utilization management, home health services for both Elevance and external health plan clients) represents the strategy of building a health services ecosystem that retains value within the Elevance enterprise rather than paying external PBMs, behavioral health managers, and care management vendors.

Full profile

AI Visibility Head-to-Head

67
Overall Score
92
#1
Category Rank
#194
84
AI Consensus
68
up
Trend
down
72
ChatGPT
88
69
Perplexity
88
68
Gemini
88
74
Claude
86
68
Grok
99

Key Details

Category
Radiopharmaceuticals
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Aktis Oncology
Radiopharmaceuticals

Integrations

Both integrate with
Only Elevance Health
Elevance Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.